Micro Pharmaceuticals
Market Cap
₹1,577 ₹1,577 Cr.
P/E
21.32
PEG
2.67
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- The thesis turns constructive if Protective Devices sustains its recovery, Medical Devices continues to scale, and the EVA and Good Home transaction proceeds as planned.- The bull path depends on stronger Protective Devices recovery and faster Medical Devices growth, while the bear path reflects renewed Protective Devices weakness, Foods pressure, or disruption around the brand transition.

Key Ratios

Debt to Equity
Debt to Equity
0.02
Div Yield (%)
Div Yield (%)
0.90
Individual < 2 lac
Individual < 2 lac
12.05 %
Institutions
Institutions
4.05 %
Market cap
Market cap
1,577 Cr
No. of Shareholders
No. of Shareholders
22,809
OPM (%)
OPM (%)
4.30 %
PE
PE
21.32
Prom Holding
Prom Holding
74.56 %
ROCE (%)
ROCE (%)
8.02
ROE (%)
ROE (%)
5.89
Sales
Sales
888 Cr
  • TTK Healthcare
  • 3B Blackbio Dx
  • Nureca
  • TJI Pharma - Small Cap
Last updated on 4 Sep 2026
  • TTK Healthcare, after selling human pharma in FY23, sells consumer goods, protective devices, foods, animal welfare and medical devices
  • Q1FY27 rebounded on Protective Devices swinging to ₹6.13Cr profit; ₹7.02Cr USAID stock sale flattered revenue; Medical margins slipped
  • Protective Devices drives volatility; Medical Devices is the growth leg; consumer goods, foods and animal welfare form the base
  • EVA/Good Home exit trims consumer exposure
  • ₹610Cr net cash plus ₹256Cr sale proceeds; allocation conservative, use undisclosed
  • Near term turns on Protective Devices repeating profit; FY27 replacement capex guided ₹20Cr
  • Reported profit repeatedly distorted by one-offs
  • Protective Devices repeat each quarter
    second straight profit after Q1 ₹6.13Cr starts durable turnaround case
  • First post-sale quarter late Oct–mid Nov 2026
    books ₹256Cr gain vs ₹0.70Cr book; post-sale mix and proceeds use disclosed
  • FY27 capex plan through FY27
    spend against ₹20Cr plan after ₹3.9Cr FY26 actual
  • Dividend and proceeds allocation May–Jun 2027
    payout vs ₹10 norm; any buyback, special dividend or deal deploys ₹256Cr proceeds
  • Labour Code cost reset No timeline
    incremental cost beyond ₹7.58Cr provision resets recurring base
Price Range

See where the stock is trading versus its 52-week high and low.

Low
735
52W Range
High
1247
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

9 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

0 %
(as of Jul 22)
Anti - Diabetes - Market Share
0 %
(as of Jul 22)
Anti-Infectives - Market Share
0.02 %
(as of Nov 21)
Antineo Plastic - Market Share
0.23 %
(as of Nov 21)
Blood Related - Market Share
0 %
(as of Jul 22)
Cardiovascular - Market Share
0.01 %
(as of Nov 21)
Dermatology - Market Share

Revenue mix

Product Wise Break-Up - Pharmaceuticals

Product Wise Break-Up - Medical Devices

Product Wise Break-Up

Segment Break-Up

Location Wise Break-Up

Operating Profit Break-Up

Asset Break-Up - Segment

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Brands

    Skore

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    FAQs on TTK Healthcare Ltd. Business

    TTK Healthcare Limited offers innovative products and solutions to enhance customers' quality of life. Its brand portfolio includes Woodward's Gripe Water and Eva personal care products, known for quality and reliability.

    TTK Healthcare major competitors are 3B Blackbio Dx, Nureca, QMS Medi Allied Ser., Poly Medicure, Amrutanjan Health., Health X Platform, Max India.
    Market Cap of TTK Healthcare is ₹1,602 Crs.
    While the median market cap of its peers are ₹976 Crs.

    TTK Healthcare seems to be less financially stable compared to its competitors.
    Altman Z score of TTK Healthcare is 7.2 and is ranked 5 out of its 8 competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Sep
    Investor Presentation Jun
    Conference Call
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material